University of Nebraska at Omaha

DigitalCommons@UNO
Computer Science Faculty Publications

Department of Computer Science

7-2004

BCL2 Translocation Defines a Unique Tumor
Subset within the Germinal Center B-Cell-Like
Diffuse Large B-Cell Lymphoma
Javeed Iqbal
University of Nebraska Medical Center

Warren G. Sanger
University of Nebraska Medical Center

Andreas Rosenwald
University of Würzburg

Diane L. Pickering
University of Nebraska Medical Center

Barbara Dave
University of Nebraska Medical Center
See next page for additional authors

Follow this and additional works at: https://digitalcommons.unomaha.edu/compscifacpub
Part of the Computer Sciences Commons
Recommended Citation
Iqbal, Javeed; Sanger, Warren G.; Rosenwald, Andreas; Pickering, Diane L.; Dave, Barbara; Dave, Sandeep; Xiao, Li; Cao, Kahai; Zhu,
Qiuming; Sherman, Simon; Hans, Christine P.; Weisenburger, Dennis D.; Greiner, Timothy C.; Gascoyne, Randy D.; Ott, German;
Müller-Hermelink, H. Konrad; Delabie, Jan; Braziel, Rita M.; Jaffe, Elaine S.; Campo, Elias; Lynch, James C.; Conners, Joseph M.;
Vose, Julie M.; Armitage, James O.; Grogan, Thomas M.; Staudt, Louis M.; and Chan, Wing C., "BCL2 Translocation Defines a Unique
Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma" (2004). Computer Science Faculty
Publications. 52.
https://digitalcommons.unomaha.edu/compscifacpub/52

This Article is brought to you for free and open access by the Department
of Computer Science at DigitalCommons@UNO. It has been accepted for
inclusion in Computer Science Faculty Publications by an authorized
administrator of DigitalCommons@UNO. For more information, please
contact unodigitalcommons@unomaha.edu.

Authors

Javeed Iqbal, Warren G. Sanger, Andreas Rosenwald, Diane L. Pickering, Barbara Dave, Sandeep Dave, Li
Xiao, Kahai Cao, Qiuming Zhu, Simon Sherman, Christine P. Hans, Dennis D. Weisenburger, Timothy C.
Greiner, Randy D. Gascoyne, German Ott, H. Konrad Müller-Hermelink, Jan Delabie, Rita M. Braziel, Elaine
S. Jaffe, Elias Campo, James C. Lynch, Joseph M. Conners, Julie M. Vose, James O. Armitage, Thomas M.
Grogan, Louis M. Staudt, and Wing C. Chan

This article is available at DigitalCommons@UNO: https://digitalcommons.unomaha.edu/compscifacpub/52

BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center
B-Cell-Like Diffuse Large B-Cell Lymphoma
Javeed Iqbal,* Warren G. Sanger,* Douglas E. Horsman,† Andreas Rosenwald,‡ Diane L.
Pickering,* Bhavana Dave,* Sandeep Dave,§ Li Xiao,* Kajia Cao,¶ Quiming Zhu,¶ Simon
Sherman,* Christine P. Hans,* Dennis D. Weisenburger,* Timothy C. Greiner,* Randy D.
Gascoyne,† German Ott,‡ H. Konrad Müller-Hermelink,‡ Jan Delabie, Rita M. Braziel,** Elaine
S. Jaffe,§ Elias Campo,†† James C. Lynch,* Joseph M. Connors,‡ Julie M. Vose,* James O.
Armitage,* Thomas M. Grogan,‡‡ Louis M. Staudt,§ and Wing C. Chan* for the
Leukemia/Lymphoma Molecular Profiling Project
From the Departments of Pathology and Microbiology, Internal Medicine, and Preventive and Societal
Medicine, and Eppley Cancer Institute,* University of Nebraska Medical Center, Omaha, Nebraska; the
Departments of Pathology and Medical Oncology,† British Columbia Cancer Agency, Vancouver, British
Columbia, Canada; the Department of Pathology,‡ University of Würzburg, Würzburg, Germany; the
Metabolism Branch and Laboratory of Pathology,§ Center for Cancer Research, National Cancer Institute,
National Institutes of Health, Bethesda, Maryland; the Department of Computer Science,¶ University of
Nebraska at Omaha, Omaha, Nebraska; the Department of Pathology, Norwegian Radium Hospital,
Oslo, Norway; the Department of Pathology,** University of Oregon Health Sciences Center, Portland,
Oregon; the Department of Pathology,†† Hospital Clinic, University of Barcelona, Barcelona, Spain; and
the Department of Pathology,‡‡ University of Arizona, Tucson, Arizona

Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed prognostically
important subgroups: germinal center B-cell-like (GCB) DLBCL, activated B cell-like (ABC) DLBCL, and
primary mediastinal large B-cell lymphoma. The t(14;18)(q32;q21) has been reported previously to
define a unique subset within the GCB-DLBCL. We evaluated for the translocation in 141 cases of DLBCL
that were successfully gene expression profiled. Using a dual-probe fluorescence in situ hybridization
assay, we detected the t(14;18) in 17% of DLBCLs and in 34% of the GCB subgroup which contained the
vast majority of positive cases. In addition, 12 t(14;18)-positive cases detected by polymerase chain
reaction assays on additional samples were added to the fluorescence in situ hybridization-positive
cases for subsequent analysis. Immunohistochemical data indicated that BCL2, BCL6, and CD10 protein
were preferentially expressed in the t(14;18)-positive cases as compared to t(14;18)-negative cases.
Within the GCB subgroup, the expression of BCL2 and CD10, but not BCL6, differed significantly between
cases with or without the t(14;18): 88% versus 24% for BCL2 and 72% versus 32% for CD10, respectively.
In the GCB-DLBCL subgroup, a heterogeneous group of genes is overexpressed in the t(14;18)-positive
subset, among which BCL2 is a significant discriminator. Interestingly, the t(14;18)-negative subset is
dominated by overexpression of cell cycle-associated genes, indicating that these tumors are
significantly more proliferative, suggesting distinctive pathogenetic mechanisms. However, despite this
higher proliferative activity, there was no significant difference in overall or failure-free survival between
the t(14;18)-positive and -negative subsets within the GCB subgroup.

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B cells with an annual
incidence of ∼25,000 cases in the United States. DLBCL is a heterogeneous entity both clinically and
morphologically. We have recently shown by gene expression profiling that DLBCL can be classified into
two major subgroups.1 The germinal center B-cell-like (GCB) subgroup expresses genes characteristic of
normal GC B cells and is associated with a good outcome after multiagent chemotherapy, whereas the
activated B-cell-like (ABC) subgroup expresses genes characteristic of activated blood B cells and is
associated with a poor clinical outcome. Nonetheless, considerable molecular heterogeneity exists
within each subgroup. A small number of DLBCL cases are unclassifiable and do not express the GCB or
ABC signature genes at a high level.2 More recently, primary mediastinal large B-cell lymphoma (PMBL)
has been identified as a distinct subgroup of DLBCL that can be distinguished by gene expression
profiling from GCB- and ABC-DLBCL.3 and 4
The t(14;18)(q32;q21) is a characteristic feature of follicular lymphoma and is considered to be the
initiating event in lymphomagenesis. The t(14;18) is the result of an error during the process of VDJ
recombination, leading to deregulation of the expression of the anti-apoptotic gene BCL2 by bringing it
into proximity of the immunoglobulin heavy chain (IgH) gene enhancer. 5, 6, 7 and 8 In our initial study of
35 cases of DLBCL, we correlatedBCL2 translocation data with gene expression profiles and showed that
the t(14;18) defines a unique subset of DLBCL within the GCB subgroup. 9 This observation suggested
that important genetic lesions are associated with a unique, identifiable gene expression profile. To
substantiate and further extend this finding, we have examined 141 new cases that were part of 240
cases of DLBCL studied by cDNA microarray for molecular predictors of survival after
chemotherapy.2 These 141 cases of DLBCL with gene expression profiles, clinical data, and genetic data
for BCL2 translocation were studied to determine: 1) the distribution of the t(14;18) among the
subgroups of DLBCL identified by gene expression profiling; 2) whether t(14;18)-positive cases have a
unique gene expression profile; and 3) whether there are differences in the tumor characteristics and
clinical behavior between cases with and without the t(14;18).

Materials and Methods
Patient Information
We studied 240 previously analyzed cases of DLBCL with clinical data and gene expression profiles
determined by complementary DNA (cDNA) microarray technology.2A panel of hemopathologists
including E Campo, ES Jaffe, G Ott, HK Müller-Hermelink, J Delabie, R Gascoyne, T Grogan, DD
Weisenburger, and WC Chan confirmed the diagnosis of DLBCL and excluded the presence of follicular
lymphoma in all patients. Informed consent was obtained and the Institutional Review Board of the
University of Nebraska approved this study.
Preparation of Tissue Microarrays (TMAs) and Immunohistochemical Studies
TMAs were prepared from cases with adequate archival paraffin-embedded tissue. Hematoxylin and
eosin-stained sections from each paraffin-embedded, formalin-fixed block were examined to define
diagnostic areas and two to five (average, four) representative 0.6-mm cores were obtained from each
case and inserted in a grid pattern into a recipient paraffin block using a tissue arrayer (Beecher
Instruments, Silver Spring, MD). Five μm sections were then cut from each TMA and stained with

antibodies to BCL2, BCL6, and CD10 as described.10 CD20 stains were performed to evaluate each core
for involvement by tumor, and each case was evaluated independently by two pathologists (CPH, DDW)
for the percentage of tumor cells stained and recorded in 10% increments. Disagreements were
resolved by joint review on a multihead microscope. For each case, the core with the highest percentage
of tumor cells stained was used for analysis. Cases were considered positive if 30% or more of the tumor
cells were stained with an antibody.10
Detection of the t(14;18)(q32;q21) by Fluorescence in Situ Hybridization (FISH)
Among the 240 cases studied by gene expression profiling, 129 cases were studied by interphase FISH
for the presence of the t(14;18)(q32;q21). To perform FISH studies, 4-μm sections were cut from the
TMA paraffin blocks and mounted on positively charged slides. The sections were dewaxed in three
changes of HEM-D (Scientific Safety Solvents, Keller, TX) followed by dehydration in 95% ethanol. They
were then treated with 0.2 N HCl for 15 minutes, rinsed in distilled-deionized water, and incubated in a
sodium thiocyanate solution at 80°C for 15 minutes. After rinsing in phosphate-buffered saline (PBS), the
sections were digested with a protease solution at 37°C for 10 minutes; postfixed in 0.95%
formaldehyde solution/PBS with 0.45% MgCl2 for 5 minutes at room temperature; rinsed in PBS; and
sequentially dehydrated in 70%, 80%, and 95% ethanol.
For FISH, the dual-color LSI IgH Spectrum Green/LSI BCL2 Spectrum Orange Dual-Fusion Translocation
Probe (Vysis, Downers Grove, IL) was used to detect the t(14;18), and the CEP 18 Spectrum Aqua probe
(Vysis) was used simultaneously to evaluate the chromosome 18 copy number. The probe mixture (10
μl) was placed on the tissue sections, coverslipped, and sealed. Hybridization was performed overnight
at 37°C using an automated hybridization chamber (HYBrite, Vysis) after denaturation at 75°C for 5
minutes. The slides were washed in 2× standard saline citrate/0.1% Nonidet P-40 for 2 minutes at 72°C
and then at room temperature for 2 minutes. Nuclei were counterstained with 4,6-diamidino-2phenylindole at a concentration of 125 ng/ml in anti-fade solution and the slides were visualized using
an Olympus BX52 fluorescence microscope. Images were captured and archived using Cytovision
software (Applied Imaging, Santa Clara, CA). To analyze the hybridization, a total of 50 to 100 nuclei
were scored per case for the presence of the t(14;18). In normal cells, an interphase nucleus will exhibit
individual red (BCL2) and green (IgH) signals. When the t(14;18) occurs, the red and green signals form
two yellow fusion signals in the interphase cell. It has been established by the University of Nebraska
Medical Center Human Genetics Laboratories that reactive lymphoid tissues show <2% positive cells at
2.5 SD for this FISH assay.
Detection of BCL2 Gene Rearrangement by Polymerase Chain Reaction
Extracted DNA from all 240 cases was tested for the t(14;18) by the polymerase chain reaction (PCR).
Amplification of the BCL2/JH translocation at the major breakpoint region (mbr) and minor cluster
region (mcr) was performed as described previously. 11 Positive controls consisted of DNA extracted
from the human B-cell lymphoma cell lines RL-7 for the mbr and DHL-16 for the mcr. Negative controls
consisted of sterile water instead of DNA, and DNA from normal peripheral blood mononuclear cells
obtained from healthy donors. Standard precautions were taken to guard against PCR contamination.
The PCR-positive cases were added to the FISH-positive cases to form a final set of 34 cases with the
t(14;18). The FISH-negative cases comprised the t(14;18)-negative group.
Analysis of Differential Gene Expression

We used the recently published Bayesian classification system to define the GCB, ABC, and unclassifiable
subgroups of DLBCL.12 We also separated cases with the PMBL gene expression profile3 into a new
subgroup, and examined the t(14;18) within each of these subgroups. The presence or absence of
the BCL2 translocation was used to supervise the discovery of differentially expressed genes between
the t(14;18)-positive and -negative cases in the GCB subgroup. The two-tailed Student's t-test was used
to compare the differences in gene expression levels. Genes differentially expressed between the two
subsets with a P value of <0.01 were selected for further analysis using the Significance Analysis of
Microarrays (SAM) approach, as described previously. 13 In addition to the P value, we also calculated
the t-statistics between the two groups and only genes that differed by a magnitude of >2.6 were
selected for further analysis.
As previously described, of the three different BCL2 clones (232714, 342181, 1336385) on the
Lymphochip microarray, only clone 232714 with a more 5′ sequence could detect message with a
truncated 3′ end because of translocation at the mbr. Overexpression ofBCL2 as measured by clone
232714 was highly correlated with the BCL2 translocation. However, clone 232714 is located far from
the 3′ end of the transcript and, therefore, may fail to measure much of the cDNA transcribed by reverse
transcription reactions starting from the poly-A tail of the normal BCL2 transcript. We used the mean
values measured by the BCL2 clones that are located close to the 3′ end (342181, 1336385) of the
transcript to represent the gene expression level in cases in which this mean value was greater than the
measurement by clone 232714.
Survival Analysis
The Kaplan-Meier method was used to estimate the overall and event-free survival of the patients, and
the log-rank test was used to compare the survival experiences between the t(14;18)-positive and negative cases. Overall survival was defined as the time from diagnosis to death from any cause or, for
patients remaining alive, the time from diagnosis to last contact. Event-free survival was defined as the
time from diagnosis to the first occurrence of relapse or death from any cause or, for patients remaining
alive and relapse-free, the time from diagnosis to last contact. SAS software (SAS Institute Inc., Cary, NC)
was used for the data analysis.

Results
Occurrence of the t(14;18) in DLBCL
Based on the results of our recent study of PMBL,3 12 GCB cases were reclassified as PMBL. Therefore,
we classified the DLBCL cases into GCB, ABC, PMBL, and unclassifiable subgroups and examined the
distribution of the t(14;18). Interphase FISH was applied to the 129 TMA cases and detected 22 cases
that were positive for the t(14;18). Based on FISH analysis, t(14;18) was detected in 17% (22 of 129) of
the cases of DLBCL which represented 34% (19 of 55) of the cases in the GCB subgroup. We also
performed PCR assays on 240 cases studied by cDNA microarray, 26 cases were found to be positive,
including 14 of the cases previously found to be positive by FISH (Figure 1). The PCR-negative cases that
were not tested by FISH were excluded from further analysis because of the recognized high falsenegative rate of the PCR assay. Thus, PCR analysis revealed an additional 12 positive cases and in this

cohort of 141 cases, 34 DLBCL cases carried the t(14;18) translocation, and 107 lacked this abnormality
(Figure 1).

Figure 1. Frequency of the t(14;18) in DLBCL. A: Among the 129 cases studied by interphase FISH for the presence of t(14;18),
22 cases were positive whereas 107 cases were negative. B: PCR analysis detected 26 positive cases, of which 14 were also
shown to be positive by FISH. Therefore, an additional 12 positive cases detected by PCR were included in this study. Thus, of
the 141 cases, 34 cases were BCL2 translocation-positive and 107 were negative.

Review of the frequency of this anomaly in relation to the DLBCL subgroups (ie, GCB, ABC, PMBL, and
unclassifiable) showed that the great majority (29 of 34) of the t(14;18)-positive cases occurred in the
GCB subgroup. In contrast, only 3 cases occurred among the 23 cases in the unclassifiable subgroup, and
none among the 41 ABC cases. Interestingly the t(14;18) translocation was found in 2 of the12 cases
categorized by gene expression profiling as PMBL3 (Figure 2).

Figure 2. Distribution of the t(14;18) among the DLBCL subgroups. Twenty-nine of 34 positive cases occurred in the GCB
subgroup, whereas three cases occurred in the unclassifiable subgroup and none in the ABC subgroup. Among 12 PMBL cases
identified using the PMBL predictor, 2 cases had the t(14;18).

Comparison with Immunohistochemical Data from the TMA
We reviewed the immunohistochemical reactions of 109 TMA samples to correlate the presence and
absence of the t(14;18) translocation with the expression of three relevant proteins, namely BCL-2
(encoded by the gene deregulated by the translocation) and two markers of normal germinal center B
cells (BCL6 and CD10).
The protein expression of BCL2 was similar in the GCB (28 of 50, 56%) and ABC (19 of 31, 61%)
subgroups, but was less frequent in the unclassifiable (6 of 19, 31%) or the PMBL subgroups (2 of 9,
22%). The difference did not reach statistical significance (P = 0.054) ( Table 1). Within the GCB subgroup
there was a significant difference (P < 0.0001) in BCL2 protein expression between thet(14;18)-positive
cases (88%) and t(14;18)-negative cases (24%) ( Table 2) indicating that the t(14;18) is highly associated
with BCL2 protein expression in this subgroup. In other subgroups BCL2 was generally up-regulated by
mechanisms other than the t(14;18), as frequently seen in the ABC cases.
Table 1. Expression of BCL2, BCL6, and CD10 in DLBCL Subgroups

Table 2. Expression of BCL2, BCL6, and CD10 with Regard to BCL2 Translocation

BCL6 protein was detected in 58% (63 of 109) of the cases of DLBCL and it was very frequently expressed
in the GCB subgroup (42 of 50, 84%; P < 0.0001), but within this category there was no correlation with
the t(14;18) translocation ( Table 3). CD10 protein expression was detected overall less commonly than
BCL6 (28%, 31 of 109), and the great majority of these cases (26 of 31) were in the GCB subgroup (Table
1). This accounted for the fact that CD10 expression was much commoner overall in t(14;18)-positive
cases than in t(14;18)-negative cases (67% versus 15%; P < 0.0001) ( Table 2).

Table 3. Expression of BCL2, BCL6, and CD10 in GCB DLBCL Cases According to BCL2 Translocation Status

Differential Gene Expression between t(14;18)-Positive and t(14;18)-Negative Cases in GCB-DLBCL
To search for genes that are differentially expressed between the t(14;18)-positive and t(14;18)-negative
cases in the GCB subgroup, we examined all informative genes among 7399 known or uncharacterized
genes on the Lymphochip.2 Clones with a P value of <0.01 were selected for SAM analysis. 13 Among the
146 clones selected, 53 clones were overexpressed in the t(14;18)-positive group and 93 clones were
overexpressed in the t(14;18)-negative group. The genes that were overexpressed in the t(14;18)positive group represented a heterogeneous set including genes involved in apoptosis
(BCL2,BAD, DRAK1, and TXBP151), a number of transcription factors (FLI1, HOX11, andBAP135) and
genes associated with cell adhesion/migration (CD62L, cytohesin-1,profilin 2, SDF1, and CD31).
Interestingly, a large number of genes overexpressed in the t(14;18)-negative group are associated with
cell cycle progression and regulation (Figure 3A). These include genes that control several events in
mitosis (PLK, KNSL5,TTK, P55CDC, ARK2, CENE, and CENF), genes involved in cell cycle progression
(CYCLIN-A, CDC2, CDC25C, and SAK) and DNA replication (HMG-I/Y, DNA helicase, and DHFR).

Figure 3. Differential gene expression in the two cytogenetic subsets of GCB-DLBCL. A: Differential expression of genes in cases
with or without t(14;18) in the GCB subgroup. Differentially expressed genes are illustrated with red indicating increased
expression and green decreased expression. Each column represents a single GCB DLBCL case and each row represents a single
gene. Among the 146 clones selected, 53 clones were overexpressed in the t(14;18)-positive group and 93 clones were
overexpressed in the t(14;18)-negative group. Genes discussed in the text are listed on the right with the number of clones
selected (when >1) indicated in the bracket. The full gene list is available in the supplemental table
at http://ajp.amjpathol.org. B: BCL2 gene expression in cases with and without the t(14;18) in the GCB subgroup. BCL2 gene
expression was calculated as detailed in the text to more accurately reflect the true expression levels. These new values
avoided the false-negative measurements because of 3′ truncation of the transcript resulting from BCL2 translocation at the
mbr and the falsely low values on many normal transcripts, when measured by the clone (232714). Using these values, BCL2 is
significantly overexpressed in the t(14;18)-positive subset (P = 0.0015 and t-statistic value = 3.35).

Some of the cDNAs were represented by multiple clones on the array and these clones were selected
independently by the computer algorithm, providing confidence in the reproducibility of the
experimental data and the analytical approach. BCL2 gene expression by the different cDNA clones had
been adjusted to obtain a more accurate measurement as described in the Materials and Methods
section. It was found to be a highly significant discriminator between the two cytogenetic groups (Figure
3B).
Correlation between the t(14;18) and Survival in the GCB Subgroup
The GCB subgroup (excluding PBML) consisted of 39 men and 26 women with a median age of 61 years
(range, 24 to 88 years). The median follow-up of the surviving patients was 7.3 years (range, 0.8 to 21.8

years) in this group. Figure 4, A and B, shows Kaplan-Meier estimates of overall and event-free survival
experiences, respectively, of the t(14;18)-positive and negative subsets of the patients in the GCB
subgroup as defined by the Bayesian classifier. P values are based on a log-rank comparison of the
outcome of the two subsets. There is no significant difference between the two cytogenetic subsets.

Figure 4. Survival of t(14;18)-positive versus t(14;18)-negative patients in the GCB DLBCL
subgroup. A: Overall survival; B: event-free survival. There is no significant difference 0in survival
between the two subsets of patients.

Discussion
DLBCL is the most common type of lymphoma, comprising 30 to 40% of all non-Hodgkin's
lymphoma.14 The recent development of DNA microarray technology provides an opportunity to take a
genome-wide approach to the study of DLBCL. We have previously identified two molecularly distinct
subtypes of DLBCL indicative of different functional stages of B-cell differentiation.1 and 2 One type
expressed genes characteristic of GC B cells (GCB-DLBCL), whereas the other type expressed genes
normally seen during in vitro activation of peripheral blood B cells (ABC-DLBCL). In a previous study, 9we
found that the t(14;18)-positive cases of DLBCL were all in the GCB group but, because of the limited
number of cases, a number of interesting questions could not be addressed. In this study, we have
examined the presence of the t(14;18) in a much larger series of DLBCL and have correlated this genetic
abnormality with the gene expression profiles, tumor characteristics, and survival of the patients. The
FISH assay detected the t(14;18) in 17% (22 of 129) of the cases and in 34% (19 of 55) of the GCB cases,
similar to our previous findings.9 By PCR analysis, we detected the translocation in an additional 12 cases
outside of the cohort studied by FISH. We observed that the vast majority (29 of 34) of the t(14;18)positive cases occurred in the GCB subgroup. These cases had a gene expression profile resembling
normal GCB cells, suggesting that this translocation plays an important role in the pathogenesis of this
subset of DLBCL, just as it does in follicular lymphoma. The complete absence of t(14;18) in the ABCDLBCL confirmed our previous observation and supported the conclusion that GCB and ABC DLBCL are
distinct pathogenetic and biological entities. Three t(14;18)-positive cases were found in the
unclassifiable subgroup. However the unclassifiable cases are not well characterized and are
heterogeneous, likely including some GCB cases with atypical profiles. Recently, Rosenwald and
colleagues3 and Savage and colleagues4 have defined a unique gene expression profile for PMBL and this
subgroup can now be distinguished from the GCB-DLBCL. It is interesting to note that a low percentage
(22%) of PMBL cases had the t(14;18), suggesting that there may be further heterogeneity within this
subgroup.
We also analyzed the immunohistochemical findings available in the cases with t(14;18) data. The vast
majority of patients with this translocation had increased BCL2 protein expression. However, BCL2
protein was also frequently present in cases without the translocation, especially in the ABC subgroup,
which characteristically had high BCL2 mRNA levels. This indicates that up-regulation of BCL2 expression
may occur by other mechanisms such as activation of the nuclear factor-kB pathway or an increased
copy number of the BCL2 gene. It is interesting to note that, in the GCB subgroup, BCL2 protein
expression was markedly different in cases with and without the t(14;18) (89%versus 37%, respectively).
BCL6 protein was more frequently expressed in the GCBversus the ABC and other subgroups, but was
not specifically correlated with the t(14;18) within the GCB subgroup. On the other hand, CD10
expression was highly specific for the GCB subgroup and was most frequently expressed in cases with
the t(14;18). In the PMBL subgroup, the majority have the immunohistochemical profile of the t(14;18)negative cases, as expected.
We also attempted to correlate the t(14;18) status with gene expression profiles within the GCB
subgroup to discover genes that characterize the two cytogenetic subsets and might provide insight into
their pathobiology. SAM analysis was used to find genes that were differentially expressed between the
two subsets after an initial data reduction based on the Student's t-test (P < 0.01). SAM analysis
identified 53 up-regulated genes in the t(14;18)-positive cases and 93 up-regulated genes for t(14;18)negative cases.BCL2 gene expression is an important discriminator between the two cytogenetic

subsets. BCL2 was overexpressed in most cases of GCB-DLBCL with the t(14;18). However, there were a
few cases in which BCL2 expression was low, indicating that overexpression of this gene may no longer
be necessary in some cases of established DLBCL. The microarray analysis was further substantiated by
BCL2 immunohistochemistry, which revealed that a high percentage (88%) of t(14;18)-positive GCBDLBCL cases had BCL2 protein expression, whereas BCL2 was expressed in only 24% of the t(14;18)negative cases. In addition to BCL2, several genes that may be involved in apoptosis were also
overexpressed in t(14;18)-positive cases including BAD, a proapoptotic gene in the BCL2 family. DRAK1,
a positive mediator of apoptosis, is related to Death-associated Protein Kinase 1 (DAP1). 15 TXBP151 is a
novel anti-apoptotic gene that has been shown to mediate the activity of A20, which is induced by
CD40/CD40L interaction, 16 and 17 and its proteolysis is associated with FAS-mediated apoptosis. IL15 was
also overexpressed in the BCL2 translocated cases and it has been implicated in protecting B cells from
apoptosis. 18 The precise functional alterations in the apoptotic pathway are difficult to predict from the
gene expression data and it is possible that the apoptotic pathway is dominated by BCL2 overexpression
in the vast majority of t(14;18)-positive cases. In addition to these genes, there is also overexpression of
a heterogeneous group of transcription factors including FLI1 that regulates expression of the TGF-β
type II receptor, 19HOX11 that belongs to a family of DNA-binding transactivators, 20 and BAP135.
BAP135 exists as a complex with Bruton Tyrosine Kinase (BTK) before B-cell antigen receptor
engagement and is transiently tyrosine-phosphorylated in response to B-cell receptor crosslinking. 21BAP135 is identical to the putative transcription factor TFII-I and there is evidence that tyrosine
phosphorylation may enhance its activity, thereby linking receptor activation with changes in gene
expression. A group of genes that have diverse functions were also overexpressed including a number of
genes that are involved in cell adhesion, migration, and cytoskeletal function: CD62L, cytohesin1, profilin 2, SDF1, and CD31. CD62L is involved in cell adhesion and migration. 22 Cytohesin-1 is a
guanine nucleotide exchange factor for ARF GTPases and is a regulator of integrin-mediated cell
adhesion.23 The function of integrins is regulated through cytoplasmic signaling, and profilin 224 may
form an important link between integrin cell adhesion signals and F-actin polymerization, as has been
postulated in T lymphocytes.25 SDF1 is a highly potent lymphocyte chemoattractant and is also involved
in intracellular actin polymerization in lymphocytes, a prerequisite for cell motility.26 CD31 has
widespread distribution and in addition to cell adhesion, may have a role in regulating cell signaling and
angiogenesis. 27 and 28
The gene expression profile associated with t(14;18)-negative cases was dominated by genes involved in
cell cycle progression and regulation. These included genes involved in regulating mitotic spindle
functions, activation of anaphase promoting complex (APC) and events essential for cytokinesis
(eg, PLK, mitotic kinesin-like protein-1, or KNSL5,P55CDC, and CKS1). 29, 30, 31 and 32 In addition to these
genes, many important regulators of cell cycle-related events including centrosome
separation/segregation (eg,ARK2), 33 kinetochore association (eg, CENF), 34 functional components of
mitotic check points (eg, CENPE and TTK orMps1), 35 and 36 chromatin association and DNA replication
(eg, HMG-I/Y, chromatin assembly factor-I (p150), DNA helicase and DHFR).37, 38 and 39 A group of genes
that promotes G2/M transit or are expressed in the M phase of the cell cycle, including CYCLINA, CDC2, CDC25C, and SAK, 40, 41 and 42 were also up-regulated. These results suggest that t(14;18)-negative
GCB-DLBCL is significantly more mitotically active than the t(14;18)-positive cases, and indicates that the
two cytogenetic subsets have distinctive biological characteristics. In normal cells, BCL2 has been
reported to retard G1/S phase progression43 and the higher expression of BCL2 in the translocated cases
may have the same effects on cell cycle progression as has been observed in developing B

lymphocytes.44 However, further studies are needed to determine whether other mechanisms are
involved in the higher expression of genes associated with cell cycle regulation and progression in the
nontranslocated subset.
Overall and failure-free survival analysis did not show any significant differences between t(14;18)positive and -negative cases within the GCB subgroup. However, there seems to be a continued
occurrence of late deaths in the t(14;18)-positive subset but this finding needs to be confirmed in a
larger series of patients.
In conclusion, we found that t(14;18) was present in a large subset of cases in the GCB-DLBCL subgroup.
This specific translocation was primarily confined to GCB-DLBCL, without any cases seen in ABC-DLBCL,
thus supporting the view that DLBCL can be divided into pathogenetically distinct subgroups with unique
gene expression profiles. Cases in the ABC subgroups also frequently overexpressed BCL2, but through
mechanisms other than t(14;18). The t(14;18)-positive subset within the GCB subgroup showed a clear
decreased expression of proliferation signature genes when compared with the t(14;18)-negative
subset. This could be partly explained by the anti-proliferation effect of BCL2, but there may be other
underlying biological mechanisms. These two subsets did not show any significant differences on
survival under conventional therapy. However, the increase in BCL2 expression in one subset and the
higher proliferative activity in the other suggest biological differences that could be exploited in future
clinical trials.
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